CN108883203A - 癌症疗法 - Google Patents

癌症疗法 Download PDF

Info

Publication number
CN108883203A
CN108883203A CN201780018603.6A CN201780018603A CN108883203A CN 108883203 A CN108883203 A CN 108883203A CN 201780018603 A CN201780018603 A CN 201780018603A CN 108883203 A CN108883203 A CN 108883203A
Authority
CN
China
Prior art keywords
days
vaccine
inhibitor
purposes
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780018603.6A
Other languages
English (en)
Chinese (zh)
Inventor
道格·麦克尼尔
理查德·莱斯尼夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madison Vaccine Co
Original Assignee
Madison Vaccine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madison Vaccine Co filed Critical Madison Vaccine Co
Publication of CN108883203A publication Critical patent/CN108883203A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
CN201780018603.6A 2016-02-12 2017-02-10 癌症疗法 Pending CN108883203A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294349P 2016-02-12 2016-02-12
US62/294,349 2016-02-12
US201662404252P 2016-10-05 2016-10-05
US62/404,252 2016-10-05
PCT/US2017/017445 WO2017139628A1 (en) 2016-02-12 2017-02-10 Cancer therapy

Publications (1)

Publication Number Publication Date
CN108883203A true CN108883203A (zh) 2018-11-23

Family

ID=59088211

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780018603.6A Pending CN108883203A (zh) 2016-02-12 2017-02-10 癌症疗法

Country Status (8)

Country Link
US (5) US11000578B2 (enExample)
EP (1) EP3413927A4 (enExample)
JP (2) JP2019512020A (enExample)
CN (1) CN108883203A (enExample)
AU (1) AU2017217940B2 (enExample)
CA (1) CA3013930C (enExample)
HK (1) HK1258319A1 (enExample)
WO (1) WO2017139628A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110632292A (zh) * 2019-06-12 2019-12-31 江苏莱尔生物医药科技有限公司 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法
CN111141906A (zh) * 2020-01-06 2020-05-12 中南大学湘雅医院 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒
CN112638947A (zh) * 2018-08-30 2021-04-09 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
CN113597314A (zh) * 2019-02-08 2021-11-02 麦迪逊疫苗公司 癌症疗法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2020097209A1 (en) * 2018-11-06 2020-05-14 Wisconsin Alumni Research Foundation Treating prostate cancer using a combination of a dna vaccine, pd-1 inhibitor and an ido inhibitor
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
WO2021108331A1 (en) * 2019-11-26 2021-06-03 The Regents Of The University Of California Combination therapy for head and neck cancer
EP4175664A2 (en) * 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023118360A1 (en) 2021-12-23 2023-06-29 Universiteit Maastricht Immunoprotective type implantable cell delivery device

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142890A1 (en) * 2002-09-27 2004-07-22 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
CN101888853A (zh) * 2007-10-18 2010-11-17 Bn免疫疗法股份有限公司 Mva用于治疗前列腺癌的用途
CN102458458A (zh) * 2009-04-17 2012-05-16 全球免疫股份有限公司 组合免疫疗法组合物和方法
CN104284674A (zh) * 2012-05-04 2015-01-14 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
US20150210769A1 (en) * 2014-01-24 2015-07-30 Novartis Ag Antibody molecules to pd-1 and uses thereof
US20160022814A1 (en) * 2014-07-18 2016-01-28 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20070232558A1 (en) 2006-03-31 2007-10-04 Mcneel Douglas G Methods and compositions for treating prostate cancer using dna vaccines directed to cancer testis antigen
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008103645A2 (en) 2007-02-19 2008-08-28 Wisconsin Alumni Research Foundation Prostate cancer and melanoma antigens
US20110301052A1 (en) 2010-04-16 2011-12-08 Mcneel Douglas G Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
US8603485B2 (en) 2011-01-05 2013-12-10 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
JP2017535599A (ja) 2014-11-07 2017-11-30 ウィスコンシン アラムニ リサーチ ファンデーション Ｂ細胞標的ｄｎａワクチン
WO2016094639A1 (en) 2014-12-10 2016-06-16 Wisconsin Alumni Research Foundation Mini-intronic plasmid dna vaccines in combination with lag3 blockade
WO2017139755A1 (en) 2016-02-12 2017-08-17 Rekoske Brian T Cancer therapy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142890A1 (en) * 2002-09-27 2004-07-22 Wisconsin Alumni Research Foundation Methods and compositions for treating prostate cancer using DNA vaccines
US20070123487A1 (en) * 2002-09-27 2007-05-31 Wisconsin Alumni Research Foundation Methods and Compositions for Treating Prostate Cancer Using DNA Vaccines
CN101888853A (zh) * 2007-10-18 2010-11-17 Bn免疫疗法股份有限公司 Mva用于治疗前列腺癌的用途
CN102458458A (zh) * 2009-04-17 2012-05-16 全球免疫股份有限公司 组合免疫疗法组合物和方法
CN104284674A (zh) * 2012-05-04 2015-01-14 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
US20150210769A1 (en) * 2014-01-24 2015-07-30 Novartis Ag Antibody molecules to pd-1 and uses thereof
US20160022814A1 (en) * 2014-07-18 2016-01-28 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRIAN T. REKOSKE等: "Abstract CN04-03: DNA vaccines as treatment for prostate cancer -understanding mechanisms of resistance", 《MOLECULAR CANCER THERAPEUTICS》 *
BRIAN T. REKOSKE等: "Antitumor vaccination of pantigen-specific immune responsesrostate cancer patients elicits PD-1/PD-L1 regulated", 《ONCOIMMUNOLOGY》 *
DOUGLAS G MCNEEL: "Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer", 《CLINICALTRIALS DATABASE》 *
DOUGLAS G. MCNEEL等: "Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer", 《CLINICAL CANCER RESEARCH》 *
田仁礼等: "肿瘤基因疫苗的研究进展", 《现代生物医学进展》 *
郑国洋等: "前列腺癌免疫治疗进展", 《中华临床医师杂志(电子版)》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638947A (zh) * 2018-08-30 2021-04-09 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
CN113597314A (zh) * 2019-02-08 2021-11-02 麦迪逊疫苗公司 癌症疗法
CN110632292A (zh) * 2019-06-12 2019-12-31 江苏莱尔生物医药科技有限公司 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法
CN111141906A (zh) * 2020-01-06 2020-05-12 中南大学湘雅医院 一种小细胞肺癌患者外周血循环肿瘤细胞及pd-l1的检测试剂盒

Also Published As

Publication number Publication date
US20170182139A1 (en) 2017-06-29
US11000578B2 (en) 2021-05-11
US20250074987A1 (en) 2025-03-06
CA3013930A1 (en) 2017-08-17
HK1258319A1 (zh) 2019-11-08
EP3413927A4 (en) 2019-11-27
JP2022088665A (ja) 2022-06-14
US20190030150A1 (en) 2019-01-31
US20240115684A1 (en) 2024-04-11
AU2017217940B2 (en) 2024-03-21
WO2017139628A1 (en) 2017-08-17
CA3013930C (en) 2025-03-18
JP2019512020A (ja) 2019-05-09
US20210283232A1 (en) 2021-09-16
AU2017217940A1 (en) 2018-08-23
EP3413927A1 (en) 2018-12-19
US11806391B2 (en) 2023-11-07

Similar Documents

Publication Publication Date Title
US11806391B2 (en) Combinatorial method of treating prostate cancer
Wargowski et al. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
EP3468584B1 (en) Combination therapy consisting of adt and an androgen receptor vaccine
WO2007001476A1 (en) Combinations of tumor-associated antigens in diagnostics for various types of cancer
CA2571070A1 (en) Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
Singh et al. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications
WO2015123532A1 (en) Ras g12r immunotherapy for ras mutation-positive cancers
CN101171032B (zh) 天然肽及其优化的衍生物作为疫苗的应用
Llopiz et al. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy
US20220211832A1 (en) Treatment methods
WO2017139755A1 (en) Cancer therapy
Knutson et al. A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
US20220133873A1 (en) Cancer therapy
KR20250099713A (ko) 항-pd-1 또는 항-pd-l1 항체를 이용한 암 치료
US20220412979A1 (en) Treatment methods
Burny et al. Measurement of the specific T-Cell response in melanoma patients immunized with a recombinant MAGE-A3 immunotherapeutic: Development of a sensitive read-out for serial monitoring
Lubkov et al. Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study Erika J. Crosby, William Gwin 2, 3, Kimberly Blackwell 2, Paul K. Marcom 2, Serena Chang 4, Holden T Maecker 4, Gloria Broadwater 5, Terry Hyslop 5, Sungjin Kim 6, Andre Rogatko 6
HK40002879A (en) Combination therapy consisting of adt and an androgen receptor vaccine
HK40002879B (en) Combination therapy consisting of adt and an androgen receptor vaccine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination